Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Nasrallah SN, Reynolds LR.

Clin Med Insights Endocrinol Diabetes. 2012;5:31-7. doi: 10.4137/CMED.S9494. Epub 2012 Apr 11.

2.

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.

Atkin S, Javed Z, Fulcher G.

Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646. Review.

3.

Treating to target in type 2 diabetes: the BEGIN trial programme.

Wangnoo SK, Chowdhury S, Rao PV.

J Assoc Physicians India. 2014 Jan;62(1 Suppl):21-6.

PMID:
25330628
4.

Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.

Muñoz Torres M.

Endocrinol Nutr. 2014 Mar;61(3):153-9. doi: 10.1016/j.endonu.2013.03.012. Epub 2013 Jul 25. Review.

PMID:
23890782
5.

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.

Havelund S, Ribel U, Hubálek F, Hoeg-Jensen T, Wahlund PO, Jonassen I.

Pharm Res. 2015 Jul;32(7):2250-8. doi: 10.1007/s11095-014-1614-x. Epub 2015 Jan 8.

6.

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.

Thuillier P, Alavi Z, Kerlan V.

Diabetes Metab Syndr Obes. 2015 Oct 1;8:483-93. doi: 10.2147/DMSO.S54953. eCollection 2015. Review.

7.

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C.

Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7.

PMID:
21396703
8.

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus.

Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H.

Diabetes Ther. 2014 Jun;5(1):255-65. doi: 10.1007/s13300-014-0070-2. Epub 2014 Jun 3.

9.

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement.

Kalra S, Latif ZA, Comlekci A, Galvez GG, Malik R, Pathan MF, Kumar A.

Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):542-5. doi: 10.4103/2230-8210.182980. Review.

10.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1489-97. doi: 10.1016/S0140-6736(12)60204-9.

PMID:
22521071
11.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
12.

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

Kerlan V, Gouet D, Marre M, Renard É.

Ann Endocrinol (Paris). 2013 Dec;74(5-6):487-90. doi: 10.1016/j.ando.2013.04.004. Epub 2013 Aug 23.

PMID:
23978337
13.

A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action.

Drab SR, Philis-Tsimikas A.

Pharmacotherapy. 2014 Mar;34(3):291-302. doi: 10.1002/phar.1361. Epub 2013 Oct 17. Review.

PMID:
24132869
14.

Efficacy and safety of ultra-long-acting insulin degludec.

Wakil A, Atkin SL.

Ther Adv Endocrinol Metab. 2012 Apr;3(2):55-9. doi: 10.1177/2042018812437181.

15.

Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study.

Landstedt-Hallin L.

Curr Med Res Opin. 2015 Aug;31(8):1487-93. doi: 10.1185/03007995.2015.1058252. Epub 2015 Jul 17.

PMID:
26046236
16.

The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.

Lajara R, Cengiz E, Tanenberg RJ.

Curr Med Res Opin. 2017 Jun;33(6):1045-1055. doi: 10.1080/03007995.2017.1298522. Epub 2017 Mar 24.

PMID:
28277867
17.

Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus.

Berard L, MacNeill G.

Can J Diabetes. 2015 Feb;39(1):4-9. doi: 10.1016/j.jcjd.2014.02.019. Epub 2014 Jul 22.

PMID:
25065475
18.

Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.

Hirose T, Awata T, Yamamoto Y, Hemmingsen MP.

Expert Opin Biol Ther. 2017 Oct 20:1-9. doi: 10.1080/14712598.2018.1389888. [Epub ahead of print]

PMID:
29017373
19.

A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.

Woo VC.

Clin Ther. 2017 Aug;39(8S2):S12-S33. doi: 10.1016/j.clinthera.2017.01.007. Epub 2017 Feb 7. Review.

PMID:
28187863
20.

Evolution of insulin development: focus on key parameters.

Tibaldi JM.

Adv Ther. 2012 Jul;29(7):590-619. doi: 10.1007/s12325-012-0034-8. Epub 2012 Jul 27. Review.

PMID:
22843207

Supplemental Content

Support Center